List view / Grid view
10 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE recommends 2 cancer drugs for routine use on the NHS as part of its programme to appraise treatments that were available on the Cancer Drugs Fund...
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund...
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
21 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Nivolumab is an intravenous drug, a form of immunotherapy that works by harnessing the power of the patient’s own immune system to destroy the cancer cells...
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Coeliac UK welcomes NICE quality standards but is concerned that many CCG's in England will not reverse blanket bans on gluten-free prescribing...
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute of Health and Care Excellence (NICE) has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia – a rare type of slow growing non-Hodgkin’s lymphoma.
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Proposed changes to the way NICE appraises new treatments could see patients benefiting from the most cost effective treatments nearly three months faster...
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
7 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Once final guidance is published, dapagliflozin will join two other similar drugs, empagliflozin and canagliflozin, as options for triple therapy...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF).
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...
